Comparative effectiveness of Class II medical devices to prevent bloodstream infections in central venous  catheters: The IVCare adaptive platform RCT

Chief Investigator

Professor Claire Rickard

Academic Institution

The University of Queensland

Date of Endorsement

16/05/2024

Outline

One in 10 hospital patients develops a hospital-acquired infection with the most lethal and costly being bloodstream infections (BSIs). One in three BSIs are caused by intravascular catheters, commonly central venous catheters, through which microorganisms enter the patient’s blood. Over 5,000 catheter line-associated BSIs (CLABSIs) occur in Australia each year including Staphylococcus aureus (30-day mortality ~30%) and antimicrobial-resistant organisms. CLABSI increases morbidity, mortality, hospital stay and costs.The Australian Register of Therapeutic Goods (ARTG) lists >2,500 TGA-approved catheter products which may prevent infection but almost none have been rigorously assessed for clinical and cost-effectiveness, adverse events, or clinician/consumer preferences. Using a novel adaptive platform randomised controlled trial (RCT) design, our highly-skilled team will assess the comparative-effectiveness of multiple class II and III medical devices to prevent CLABSI.